Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Rhea-AI Summary

Vistagen (Nasdaq: VTGN) reported financial results for Q1 FY2025 and provided a corporate update. Key highlights include:

1. PALISADE Phase 3 Program for fasedienol in Social Anxiety Disorder (SAD) is progressing on track.

2. R&D expenses increased to $7.6 million, up from $4.2 million in Q1 FY2024.

3. G&A expenses rose to $4.6 million, compared to $3.0 million in Q1 FY2024.

4. Net loss widened to $10.7 million, versus $6.9 million in Q1 FY2024.

5. Cash, cash equivalents, and marketable securities stood at $108.4 million as of June 30, 2024.

6. The company is also advancing itruvone for Major Depressive Disorder and PH80 for menopausal hot flashes.

Positive

• PALISADE-3 Phase 3 trial for fasedienol in SAD is on track to produce top-line results in 2025
• Preparations for PALISADE-4 Phase 3 trial are progressing as planned for initiation in H2 2024
• Successful completion of U.S. IND-enabling program for itruvone in MDD
• Strong cash position of $108.4 million as of June 30, 2024

Negative

• Net loss increased to $10.7 million from $6.9 million year-over-year
• R&D expenses rose to $7.6 million from $4.2 million year-over-year
• G&A expenses increased to $4.6 million from $3.0 million year-over-year

Insights

Financial Analyst

Vistagen's Q1 FY2025 results reveal a significant increase in R&D expenses to $7.6 million, up from $4.2 million in the same quarter last year. This 81% jump is primarily due to the advancement of their PALISADE Phase 3 program for fasedienol in Social Anxiety Disorder (SAD). The net loss widened to $10.7 million from $6.9 million, reflecting the company's increased investment in clinical development.

Despite the increased spending, Vistagen maintains a strong cash position of $108.4 million. This provides a substantial runway for their ongoing clinical trials and potential commercialization efforts. The company's focus on novel, non-systemic treatments for psychiatric disorders could position them well in a market seeking alternatives to traditional therapies with significant side effects.

Medical Research Analyst

Vistagen's progress with fasedienol for SAD is noteworthy. As the first company to report a positive Phase 3 trial for an acute SAD treatment, they're pioneering a new therapeutic approach. The ongoing PALISADE-3 and upcoming PALISADE-4 trials could potentially lead to an NDA submission, addressing a significant unmet need in anxiety treatment.

The company's pipeline diversity is impressive, with itruvone for major depressive disorder (MDD) and PH80 for menopausal hot flashes both advancing. These non-systemic, nose-to-brain therapies offer potential advantages over current treatments, particularly in terms of side effect profiles. The progress towards U.S. IND submissions for both compounds indicates a well-managed development strategy across multiple indications.

PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, and provided a corporate update.

“Building on the success of our PALISADE-2 Phase 3 trial of fasedienol, our rapid-onset, non-systemic pherine nasal spray for the acute treatment of social anxiety disorder, our top priority remains driving forward our U.S. registration-directed PALISADE Phase 3 program for fasedienol. Our PALISADE-3 Phase 3 trial is underway and on track and preparations to initiate our PALISADE-4 Phase 3 trial are progressing as planned,” said Shawn Singh, Chief Executive Officer of Vistagen. “In addition to fasedienol, we are excited about the progress in our other two lead pherine development programs, itruvone for major depressive disorder and PH80 for menopausal hot flashes. With novel non-systemic mechanisms of action utilizing nose-to-brain neural circuits, each of our pherine clinical-stage programs has potential to transform current treatment paradigms, set new standards of care, and improve the lives of millions of underserved individuals.”

Fasedienol for the Acute Treatment of Social Anxiety Disorder (SAD)

• Vistagen’s PALISADE-3 Phase 3 trial remains on track to produce top-line results in 2025, in line with previous guidance.
• Vistagen’s preparations to initiate its PALISADE-4 Phase 3 trial as planned in the second half of 2024 and to produce top-line results in 2025 are also on track.
• There is no FDA-approved acute treatment for SAD. Vistagen’s PALISADE-3 and PALISADE-4 Phase 3 trials are designed similarly to the Company’s positive PALISADE-2 Phase 3 trial of fasedienol for the acute treatment of SAD reported in 2023. With PALISADE-2, Vistagen became the first company to report a positive Phase 3 trial of a new drug candidate for the acute treatment of SAD. Vistagen believes either PALISADE-3 or PALISADE-4, if successful, together with the positive results from PALISADE-2, may establish substantial evidence of the effectiveness of fasedienol in support of a potential fasedienol U.S. New Drug Application (NDA) submission to the FDA for the acute treatment of anxiety in adults with SAD.

Itruvone for Major Depressive Disorder (MDD)

• Leveraging positive results from an exploratory Phase 2A trial in MDD previously conducted in Mexico, Vistagen completed its successful U.S. Investigational New Drug (IND)-enabling program to facilitate further Phase 2 development of itruvone in the U.S. Preparations and planning for a Phase 2B trial of itruvone are ongoing, with a primary focus to develop itruvone as a novel, non-systemic, stand-alone treatment for MDD without the sexual side effects, weight gain, and safety concerns associated with current depression therapies.

PH80 for Vasomotor Symptoms (Hot Flashes) due to Menopause

• Following positive results from an exploratory Phase 2A trial conducted in Mexico, similar to its successful U.S. IND-enabling program for itruvone in MDD, Vistagen’s ongoing U.S. IND-enabling program is designed to support its planned submission of a U.S. IND to facilitate further Phase 2 clinical development of PH80 in the U.S., with a primary focus on its potential as a novel non-systemic, hormone-free treatment option for millions of women affected by vasomotor symptoms (hot flashes) due to menopause.

Financial Results for Fiscal Year 2025 First Quarter Ended June 30, 2024

Research and development (R&D) expenses

• R&D expenses were $7.6 million for the three months ended June 30, 2024, as compared to $4.2 million for the three months ended June 30, 2023. The increase in R&D expenses was primarily due to an increase in clinical and development expenses related to the commencement of the Company’s PALISADE-3 Phase 3 trial, and costs related to preparations for the initiation of its PALISADE-4 Phase 3 trial of fasedienol in SAD, an increase in headcount costs, and an increase in consulting and professional fees.

General and administrative (G&A) expenses

• G&A expenses were $4.6 million for the three months ended June 30, 2024, as compared to $3.0 million for the three months ended June 30, 2023. The increase in G&A expenses was primarily due to an increase in headcount costs and professional service expenses to support the continued expansion of administrative activities.

Net loss

• Net loss was $10.7 million for the three months ended June 30, 2024, as compared to $6.9 million for the three months ended June 30, 2023.

Other financial highlights

• Cash, cash equivalents, and marketable securities were $108.4 million as of June 30, 2024.

Conference Call:

Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.

U.S. Dial-in (Toll-Free): 1-877-407-9716
International Dial-in Number (Toll): 1-201-493-6779
Conference ID: 13748020
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1680978&tp_key=f7af16cbaa

A live audio conference call webcast will also be available via the above link. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Tuesday, August 13, 2024. To listen to the replay, call toll-free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay access ID number 13748020.

About Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder

Fasedienol is a first-in-class, rapid-onset investigational pherine nasal spray with a novel proposed mechanism of action (MOA) that is differentiated from all currently approved anxiety medications. Fasedienol’s proposed MOA regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic autonomic nervous system, without systemic distribution, potentiation of GABA-A receptors, or direct activity on neurons in the brain. Vistagen’s U.S. registration-directed PALISADE Phase 3 program for fasedienol is focused on the acute treatment of SAD. Fasedienol has not demonstrated any signals of abuse potential or physical dependence in any clinical trial conducted to date. There is no FDA-approved acute treatment for SAD. The FDA has granted Fast Track designation for the investigation of fasedienol for the acute treatment of SAD.

About Itruvone Nasal Spray for Major Depressive Disorder

Itruvone is an investigational pherine nasal spray with a novel, rapid-onset proposed neurocircuitry-focused mechanism of action (MOA) that is fundamentally differentiated from the MOA of all currently approved treatments for depression disorders. Itruvone is administered intranasally at microgram-level doses and is designed to engage and activate chemosensory neurons in the nasal cavity connected to neural circuits in the brain that produce antidepressant effects. Specifically, itruvone’s proposed MOA involves the regulation of the olfactory-to-amygdala neural circuitry and is believed to increase the activity of the limbic-hypothalamic sympathetic nervous system and increase the release of catecholamines. Importantly, unlike all currently approved oral antidepressants and ketamine-based therapy (KBT), including both intravenous ketamine and intranasal ketamine, we believe itruvone has potential to achieve antidepressant effects without systemic absorption or brain penetration and without many of the side effects and safety concerns potentially associated with currently approved antidepressants requiring systemic distribution. The FDA has granted Fast Track designation for the development of itruvone as a potential treatment for major depressive disorder.

About PH80 Nasal Spray for Vasomotor Symptoms (Hot Flashes) Due to Menopause

PH80 is a hormone-free investigational neuroactive pherine nasal spray with a novel neurocircuitry-focused mechanism of action (MOA) that is fundamentally differentiated from all currently approved treatment options for women’s health indications. PH80’s proposed MOA does not require systemic absorption or direct activity on neurons in the brain. Vistagen is developing PH80 as a potential new non-systemic, hormone-free treatment for the management of vasomotor symptoms (hot flashes) due to menopause.

About Vistagen

Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on its pioneering approach and deep understanding of nose-to-brain neurocircuitry. Designed exclusively as nasal sprays administered at microgram level doses with novel non-systemic mechanisms of action, Vistagen’s diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact olfactory system and brain neurocircuitry. Favorable safety profiles have been observed in all clinical studies of Vistagen’s pherine product candidates completed to date. Vistagen’s neuroscience pipeline also includes an oral prodrug with the potential to modulate NMDA receptor activity in multiple neurological conditions, such as levodopa-induced dyskinesia associated with Parkinson’s disease therapy and neuropathic pain. At Vistagen, we are passionate about creating novel and differentiated treatments that set new standards of care for millions of people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.

Forward-looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen Therapeutics, Inc. (Vistagen or the Company) and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Among other things, there can be no guarantee that any of the Company’s drug candidates will successfully complete ongoing or, if initiated, planned or future clinical trials, receive regulatory approval or be commercially successful, or that the Company will be able to successfully replicate the result of past studies of its product candidates, including fasedienol, itruvone, PH80 or its other drug candidates. Other factors that may cause such a difference include, without limitation, risks and uncertainties relating to delays in launching, conducting and/or completing ongoing and planned nonclinical studies and clinical trials, including PALISADE-3 and PALISADE-4 or additional Phase 2 clinical trials of itruvone or PH80; the period over which the Company anticipates its available financial resources will fund its operating expenses; the timing of completion of preclinical studies and clinical trials and related preparatory work required to apply for an maintain regulatory approval for any of the Company’s drug candidates; the scope and enforceability of the Company’s patents, including patents related to the Company’s pherine drug candidates and AV-101; fluctuating costs of materials and other resources and services required to conduct the Company’s ongoing and/or planned clinical and nonclinical trials; market conditions; the impact of general economic, industry or political conditions in the United States or internationally; and other technical and unexpected hurdles in the development, manufacture and commercialization of the Company’s product candidates. These risks are more fully discussed in the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2024, and in the Company’s most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). The Company’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

VISTAGEN THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS
	June 30, 2024				March 31, 2024
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	102,918			$	119,166
Marketable securities		5,446				-
Prepaid expenses and other current assets		2,474				1,506
Total current assets		110,838				120,672
Property and equipment, net		489				435
Right-of-use asset - operating lease		1,703				1,820
Other assets		518				726
Total assets	$	113,548			$	123,653
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,209			$	1,547
Accrued expenses		2,164				2,235
Deferred revenue - current portion		2,296				791
Operating lease obligation - current portion		567				550
Total current liabilities		6,236				5,123
Deferred revenue - non-current portion		1,086				2,674
Operating lease obligation - non-current portion		1,423				1,570
Total liabilities		8,745				9,367
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2024 and March 31, 2024; no shares outstanding at June 30, 2024 and March 31, 2024		-				-
Common stock, $0.001 par value; 325,000,000 shares authorized at June 30, 2024 and March 31, 2024; 27,059,629 and 27,029,731 shares issued at June 30, 2024 and March 31, 2024, respectively		27				27
Additional paid-in capital		475,689				474,441
Treasury stock, at cost, 4,522 shares of common stock held at June 30, 2024 and March 31, 2024		(3,968	)			(3,968	)
Accumulated other comprehensive income		2				-
Accumulated deficit		(366,947	)			(356,214	)
Total stockholders’ equity		104,803				114,286
Total liabilities and stockholders’ equity	$	113,548			$	123,653

VISTAGEN THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)
	Three Months Ended June 30,
		2024				2023
Revenues:
Sublicense and other revenue	$	84			$	177
Total revenues		84				177
Operating expenses:
Research and development		7,648				4,197
General and administrative		4,567				2,978
Total operating expenses		12,215				7,175
Loss from operations		(12,131	)			(6,998	)
Other income, net:
Interest income, net		1,398				98
Loss before income taxes		(10,733	)			(6,900	)
Income taxes		-				(3	)
Net loss	$	(10,733	)		$	(6,903	)
Unrealized gain on marketable securities		2				—
Comprehensive loss	$	(10,731	)		$	(6,903	)
Basic and diluted net loss per common share	$	(0.35	)		$	(0.94	)
Weighted average common shares outstanding, basic and diluted		30,603,435				7,337,005

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240813123148/en/

Investors Inquiries:

Mark A. McPartland

(650) 577-3606

markmcp@vistagen.com

Media Inquiries:

Caren Scannell

(650) 577-3601

cscannell@vistagen.com

Source: Vistagen

FAQ

What were Vistagen's (VTGN) Q1 FY2025 financial results?

Vistagen reported a net loss of $10.7 million, R&D expenses of $7.6 million, and G&A expenses of $4.6 million for Q1 FY2025. The company had $108.4 million in cash, cash equivalents, and marketable securities as of June 30, 2024.

What is the status of Vistagen's (VTGN) PALISADE Phase 3 program for fasedienol?

The PALISADE-3 Phase 3 trial is on track to produce top-line results in 2025. Preparations for the PALISADE-4 Phase 3 trial are progressing as planned, with initiation expected in the second half of 2024.

What other drug candidates is Vistagen (VTGN) developing?

In addition to fasedienol for Social Anxiety Disorder, Vistagen is developing itruvone for Major Depressive Disorder and PH80 for menopausal hot flashes.

When does Vistagen (VTGN) expect to release top-line results for the PALISADE-3 and PALISADE-4 trials?

Vistagen expects to produce top-line results for both PALISADE-3 and PALISADE-4 Phase 3 trials in 2025.